Research that Identifies
Undiscovered Value in the MicroCap Market


Novadaq Tech Email List: Click to Subscribe

View Company Website: Click to View

Market Data: Yahoo Finance, Bloomberg, SEC Filings

Report Link: Final Update Released (Dated 04/20/2017)

Symbol: NVDQ
Analyst: Juan Noble
Taglich Rating: Suspended
Price Target: NA
Time Horizon: NA
Rating Established: April 20, 2017
Price When Established: $7.42
Most Recent Report: April 20, 2017
Price When Issued: $7.42

What's New

New information will be posted soon...

Company Description

Novadaq has commercialized SPY Imaging, a patented visualization technology that enables surgeons to monitor circulation and tissue perfusion intraoperatively, facilitating surgical mapping and revisions during major procedures. The technology can also visualize lymphatic systems, potentially detecting the extent of lymph node involvement in cancer cases, and differentiate between normal and cancerous tissue on the margins of a surgical resection.

Recent studies have demonstrated improvements in surgical outcomes, reductions in post-operative complications and cost savings stemming from the adoption of fluorescence angiography. These results should underlie wide acceptance of Novadaq’s SPY systems, which are adaptable for use in a wide variety of major surgeries. SPY systems have so far been used widely in post-mastectomy breast reconstruction and coronary artery bypass graft procedures. Variants of SPY have been developed for use in urological, gastrointestinal, and organ transplant procedures. The technology has also been refined by Novadaq for use in a number of open, minimally invasive, and robotic surgical procedures.

Novadaq’s growth strategy is based in part on strategic partnerships, the first of which, with Intuitive Surgical, could potentially boost revenue substantially in 2010.

Company Reports

Updated Research Report (Dated April 20, 2017)
Updated Research Report (Dated March 10, 2017)
Updated Research Report (Dated November 28, 2016)
Updated Research Report (Dated August 11, 2016)
Updated Research Report (Dated May 10, 2016)
Updated Research Report (Dated February 26, 2016)
Updated Research Report (Dated November 11, 2015)
Updated Research Report (Dated August 5, 2015)
Updated Research Report (Dated May 14, 2015)
Updated Research Report (Dated March 16, 2015)
Updated Research Report (Dated November 11, 2014)
Updated Research Report (Dated August 11, 2014)
Updated Research Report (Dated May 19, 2014)
Updated Research Report (Dated February 11, 2014)
Updated Research Report (Dated November 5, 2013)
Updated Research Report (Dated August 5, 2013)
Updated Research Report (Dated May 10, 2013)
Updated Research Report (Dated February 20, 2013)
Updated Research Report (Dated November 14, 2012)
Updated Research Report (Dated August 9, 2012)
Updated Research Report (Dated May 11, 2012)
Updated Research Report (Dated February 27, 2012)
Updated Research Report (Dated November 16, 2011)
Updated Research Report (Dated August 12, 2011)
Updated Research Report (Dated May 20, 2011)
Updated Research Report (Dated April 6, 2011)
Updated Research Report (Dated December 8, 2010)
Updated Research Report (Dated August 23, 2010)
Updated Research Report (Dated May 18, 2010)
Updated Research Report (Dated April 13, 2010)
Updated Research Report (Dated December, 15 2009)
Updated Earnings Note (Dated November 12, 2009)
Initial Research Report (Dated October 9, 2009)


The information and statistical data contained herein have been obtained from sources, which we believe to be reliable but in no way are warranted by us as to accuracy or completeness. We do not undertake to advise you as to changes in figures or our views. This is not a solicitation of any order to buy or sell. Taglich Brothers, Inc. is fully disclosed with its clearing firm, Pershing, LLC, is not a market maker and does not sell to or buy from customers on a principal basis. The above statements are the opinion of Taglich Brothers, Inc. and are not a guarantee that the target price for the stock will be met or that predicted business results for the company will occur. There may be instances when fundamental, technical and quantitative opinions contained in the reports are not in concert. We, our affiliates, any officer, director or stockholder or any member of their families may from time to time purchase or sell any of the above-mentioned or related securities. Analysts and members of the Research Department are prohibited from buying or selling securities issued by the companies that Taglich Brothers, Inc. has a research relationship with, except if ownership of such securities was prior to the start of such relationship, then an Analyst or member of the Research Department may sell such securities after obtaining expressed written permission from Compliance. All research issued by Taglich Brothers, Inc. is based on public information. Taglich Brothers, Inc. does not currently have an Investment Banking relationship with the company mentioned and was not a manager or co-manager of any offering for the company within the last three years. The company will pay to Taglich Brothers, Inc. a monetary fee of US$15,000 for the creation and dissemination of research reports for a nine-month period. Payment shall be made in US$3,000 increments on each of the following dates: October 1, 2009: January 1, 2010, and April1, 2010.